PMID: 11605160Oct 18, 2001Paper

Inotropes and beta-blockers: is there a need for new guidelines?

Journal of Cardiac Failure
M R BristowB D Lowes

Abstract

Beta-adrenergic blocking agents are standard treatment for patients with mild-to-moderate heart failure. When patients receiving beta-blockers decompensate they often need treatment with a positive inotropic agent. The beta-agonist dobutamine may not produce much increase in cardiac output during full-dose beta-blocker treatment and may increase systemic vascular resistance via alpha-adrenergic stimulation. In contrast, phosphodiesterase inhibitors (PDEIs) such as milrinone or enoximone retain full hemodynamic effects during complete beta-blockade because the site of action of PDEIs is beyond the beta-adrenergic receptor and because beta-blockade reverses some of the desensitization phenomena that account for the attenuation of PDEI response in heart failure related to upregulation in G(alphai). Inotrope-requiring subjects with decompensated heart failure who are undergoing long-term therapy with beta-blocking agents should be treated with a type III-specific PDEI, not a beta-agonist such as dobutamine.

Citations

Mar 18, 2003·The Journal of Clinical Investigation·Kobra HaghighiEvangelia G Kranias
Jan 29, 2005·Journal of Cardiovascular Pharmacology and Therapeutics·Shiyam SatwaniJagat Narula
Jan 23, 2009·European Journal of Heart Failure·Alexandre MebazaaAlain Cohen-Solal
Aug 5, 2016·Pediatric Critical Care Medicine : a Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies·Timothy M Hoffman
Jun 2, 2005·Circulation·Douglas L Mann, Michael R Bristow
Jul 17, 2015·Circulation. Heart Failure·Taimoor HashimDeepak Acharya
Sep 13, 2019·Circulation Journal : Official Journal of the Japanese Circulation Society·Hiroyuki TsutsuiUNKNOWN Japanese Circulation Society and the Japanese Heart Failure Society Joint Working Group
Mar 30, 2005·International Anesthesiology Clinics·Young Lan Kwak
Nov 3, 2005·Nature Clinical Practice. Cardiovascular Medicine·David S FeldmanMichael R Bristow
Feb 26, 2008·British Journal of Hospital Medicine·N R BannerS Rahman-Haley
Mar 8, 2003·Circulation Research·Steven R Houser, Kenneth B Margulies
Dec 18, 2010·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·James C CoonsSrinivas Murali
Aug 25, 2006·Current Heart Failure Reports·Rami Alharethi, Ray E Hershberger
Feb 22, 2014·Journal of Cardiac Failure·David J WhellanUNKNOWN Quality of Care Committee, Heart Failure Society of America

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.